Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Shares, No Par Value
-
Shares outstanding
-
28,495,649
-
Number of holders
-
55
-
Total 13F shares, excl. options
-
30,115,573
-
Shares change
-
+719,098
-
Total reported value, excl. options
-
$71,976,746
-
Value change
-
+$2,784,833
-
Put/Call ratio
-
31%
-
Number of buys
-
34
-
Number of sells
-
20
-
Price
-
$2.39
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q4 2020
As of 31 Dec 2020 Oncocyte Corporation - Common Shares, No Par Value (OCX) had 55 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 30,115,573 shares of stock of the company.
Largest 10 holders included BROADWOOD CAPITAL INC, PURA VIDA INVESTMENTS, LLC, BlackRock Inc., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, Penbrook Management LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, Nuveen Asset Management, LLC, and GSA CAPITAL PARTNERS LLP.
This table shows 55 institutional shareholders of the security as of 31 Dec 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.